Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis

The present study evaluated the relative survival benefits associated with enasidenib and current standard of care (SoC) therapies for patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and an isocitrate dehydrogenase 2 (IDH2) mutation who are ineligible for hematopoietic stem cell transplantation (HSCT).

[1]  C. Récher,et al.  Outcome of AML patients with IDH2 mutations in real world before the era of IDH2 inhibitors. , 2019, Leukemia research.

[2]  I. Flinn,et al.  Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. , 2019, Blood.

[3]  C. Dinardo,et al.  SOHO State of the Art Update and Next Questions: IDH Therapeutic Targeting in AML , 2018, Clinical lymphoma, myeloma & leukemia.

[4]  I. Kline,et al.  Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study , 2018, JAMA oncology.

[5]  N. Daver,et al.  Current and emerging therapies for patients with acute myeloid leukemia: a focus on MCL-1 and the CDK9 pathway. , 2018, American Journal of Managed Care.

[6]  N. Daver,et al.  Unmet clinical needs and economic burden of disease in the treatment landscape of acute myeloid leukemia. , 2018, The American journal of managed care.

[7]  Georg Heinze,et al.  Weighted Cox Regression Using the R Package coxphw , 2018 .

[8]  I. Flinn,et al.  Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. , 2017, Blood.

[9]  D. Lubeck,et al.  Systematic Literature Review of the Global Incidence and Prevalence of Myelodysplastic Syndrome and Acute Myeloid Leukemia , 2016 .

[10]  H. Kantarjian,et al.  A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase , 2016, Cancer.

[11]  J. Kell.  Considerations and challenges for patients with refractory and relapsed acute myeloid leukaemia. , 2016, Leukemia research.

[12]  I. de Kouchkovsky,et al.  ‘Acute myeloid leukemia: a comprehensive review and 2016 update' , 2016, Blood Cancer Journal.

[13]  E. Stuart,et al.  Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies , 2015, Statistics in medicine.

[14]  E. Stein.  IDH2 inhibition in AML: Finally progress? , 2015, Best practice & research. Clinical haematology.

[15]  E. Stuart,et al.  The performance of inverse probability of treatment weighting and full matching on the propensity score in the presence of model misspecification when estimating the effect of treatment on survival outcomes , 2015, Statistical methods in medical research.

[16]  H. Kantarjian,et al.  Improving outcomes for patients with acute myeloid leukemia in first relapse: A single center experience , 2015, American journal of hematology.

[17]  E. Estey,et al.  Management of older or unfit patients with acute myeloid leukemia , 2014, Leukemia.

[18]  P. Austin,et al.  The performance of different propensity score methods for estimating absolute effects of treatments on survival outcomes: A simulation study , 2014, Statistical methods in medical research.

[19]  P. Austin.  The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments , 2013, Statistics in medicine.

[20]  Benjamin L. Ebert,et al.  (R)-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible , 2013, Science.

[21]  D. Weisdorf,et al.  Survival for older patients with acute myeloid leukemia: a population-based study , 2012, Haematologica.

[22]  R. Porcher,et al.  Propensity score applied to survival data analysis through proportional hazards models: a Monte Carlo study , 2012, Pharmaceutical statistics.

[23]  Gary King,et al.  MatchIt: Nonparametric Preprocessing for Parametric Causal Inference , 2011 .

[24]  P. Austin.  An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies , 2011, Multivariate behavioral research.

[25]  Marie Davidian,et al.  Doubly robust estimation of causal effects. , 2011, American journal of epidemiology.

[26]  J. Licht,et al.  Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. , 2010, Cancer cell.

[27]  Tak W. Mak,et al.  Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations , 2010, The Journal of experimental medicine.

[28]  Elizabeth A Stuart,et al.  Matching methods for causal inference: A review and a look forward. , 2010, Statistical science : a review journal of the Institute of Mathematical Statistics.

[29]  Peter C Austin,et al.  Some Methods of Propensity‐Score Matching had Superior Performance to Others: Results of an Empirical Investigation and Monte Carlo simulations , 2009, Biometrical journal. Biometrische Zeitschrift.

[30]  C. Carey.  United States food and drug administration , 2020 .

[31]  Andrea Manca,et al.  NICE DSU TECHNICAL SUPPORT DOCUMENT 17: THE USE OF OBSERVATIONAL DATA TO INFORM ESTIMATES OF TREATMENT EFFECTIVENESS IN TECHNOLOGY APPRAISAL: METHODS FOR COMPARATIVE INDIVIDUAL PATIENT DATA , 2015 .

[32]  H. Kantarjian,et al.  Acute myeloid leukemia , 2018, Methods in Molecular Biology.